Abstract
AbstractThis invention from Astra AB discloses several novel substituted tricyclic imidazol [1,2–1] pyridines containing a dihydroxymethyl substituent at the 3-postion. The preferred compound is 3-hydroxymethyl-2-methyl-9-phenyl-7H-8,9-dihydropyrano-(2,3-c)-imidazo-(1,2-a)-pyridine. This compound inhibits exogenously and endogenously stimulated gastric acid secretion. Potential uses of the claimed compounds may be more specific, in that they may be used for the prevention and treatment of gastric acid-related diseases such as gastritis, gastric ulcers, duodenal ulcers and reflex oesophagitis. Additional claims are also made for the use of the compounds where anti-acid secretory activity is desired. These conditions include gastrinomas, upper gastrointestinal bleeding, prevention of gastric acid aspiration and stress ulcers. The invention makes a general statement that the compounds may be used for the prevention and treatment of gastrointestinal inflammatory diseases, but the claim is not well substantiated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
